Leadership Overview
NAMSA has 7 executives leading key functions including operations, financial management, revenue growth, human resources, medical oversight, and laboratory services.
Focused on accelerating medical device development, NAMSA delivers integrated laboratory, clinical research, and regulatory consulting services to improve global patient health outcomes through rigorous scientific excellence.
Focused on accelerating medical device development, NAMSA delivers integrated laboratory, clinical research, and regulatory consulting services to improve global patient health outcomes through rigorous scientific excellence.
Leadership Roles at NAMSA
Scott Sellick - Chief Financial Officer
Scott Sellick, the Chief Financial Officer at NAMSA, manages the fiscal health and long-term financial strategy of the organization. Sellick oversees capital allocation, budgeting, and financial reporting to support the expansion of laboratory and clinical research capabilities. The Chief Financial Officer evaluates investment opportunities in new technologies and service lines to maintain a competitive edge in the medical device market. Scott Sellick directs financial planning and analysis to ensure the company meets its revenue targets while maintaining operational efficiency. By providing data-driven insights to the board, the Chief Financial Officer facilitates informed decision-making regarding global market expansion and resource distribution. This role requires rigorous oversight of financial controls and risk management protocols. Through disciplined fiscal management, Sellick secures the financial stability necessary for the company to continue providing high-value consulting services to medical device manufacturers worldwide.
Elizabeth Kempen - Chief Operating Officer
Elizabeth Kempen, the Chief Operating Officer at NAMSA, directs all internal operational workflows to ensure seamless integration across laboratory and clinical research divisions. Kempen optimizes resource allocation to accelerate medical device product development cycles for global clients. By refining internal processes, the Chief Operating Officer maintains high standards of regulatory compliance and service delivery efficiency. Elizabeth Kempen monitors cross-departmental performance metrics to identify bottlenecks and implement scalable solutions. This leadership role involves close collaboration with the executive team to align operational capacity with market demand. Through the implementation of advanced project management frameworks, Kempen drives organizational productivity and supports the overarching mission of delivering high-quality research services. The Chief Operating Officer ensures that all operational activities remain consistent with the strategic goals of the organization, ultimately fostering long-term growth and operational excellence within the competitive medical research landscape.
Gina Skolmowski - Global Division President, Laboratory Services
Gina Skolmowski, the Global Division President, Laboratory Services at NAMSA, directs the operations and strategic growth of the company's extensive laboratory testing facilities. Skolmowski oversees the implementation of advanced testing methodologies and ensures compliance with international quality standards for medical device evaluation. The Global Division President, Laboratory Services manages the technical infrastructure and personnel required to deliver high-precision laboratory results for global clients. Gina Skolmowski drives continuous improvement initiatives to enhance testing throughput and accuracy. By aligning laboratory capabilities with the evolving needs of the medical device industry, the Global Division President, Laboratory Services supports the company's mission to accelerate product development. This role involves coordinating with clinical and regulatory teams to provide comprehensive, integrated service solutions. Through effective leadership of the laboratory division, Skolmowski ensures that the company maintains its reputation for scientific excellence and reliable data generation in the global marketplace.
Andrew Suri - Lead Business Development Executive & Chief Revenue Officer
Andrew Suri, the Lead Business Development Executive & Chief Revenue Officer at NAMSA, architects the commercial strategy to drive revenue growth across the medical device consulting sector. Suri identifies emerging market opportunities and cultivates strategic partnerships with global manufacturers. The Lead Business Development Executive & Chief Revenue Officer aligns sales initiatives with the company's laboratory and clinical research service offerings to maximize market penetration. Andrew Suri leads the commercial team in executing complex contract negotiations and client acquisition strategies. By analyzing market trends, the Lead Business Development Executive & Chief Revenue Officer ensures that service delivery remains relevant to evolving regulatory and reimbursement landscapes. This leadership role involves coordinating with technical teams to tailor solutions for diverse client needs. Through proactive business development, Suri expands the company's footprint in key international markets, ensuring consistent revenue streams and sustained commercial success.
Roseanne Sawyer - Chief Human Resources Officer
Roseanne Sawyer, the Chief Human Resources Officer at NAMSA, directs the talent acquisition and organizational development strategies essential for maintaining a high-performing workforce. Sawyer oversees recruitment, employee engagement, and professional development programs tailored to the specialized needs of medical research professionals. The Chief Human Resources Officer fosters a culture of innovation and scientific excellence by implementing robust training and retention initiatives. Roseanne Sawyer manages workforce planning to ensure the company possesses the necessary expertise to support complex clinical and regulatory projects. By aligning human capital strategies with business objectives, the Chief Human Resources Officer drives organizational agility and employee satisfaction. This role involves collaborating with leadership to cultivate a diverse and inclusive environment that attracts top-tier talent. Through strategic talent management, Sawyer ensures the organization remains equipped to meet the rigorous demands of the medical device industry while supporting long-term growth.
Alexa Liantonio - Senior Global Business Development Executive & Chief Revenue Officer
Alexa Liantonio, the Senior Global Business Development Executive & Chief Revenue Officer at NAMSA, spearheads international expansion efforts to capture market share in the global medical device consulting space. Liantonio develops and executes high-level sales strategies focused on large-scale clinical research and regulatory service contracts. The Senior Global Business Development Executive & Chief Revenue Officer analyzes regional market dynamics to tailor service offerings for diverse international regulatory environments. Alexa Liantonio coordinates with cross-functional teams to ensure that global client requirements are met with precision and speed. By fostering long-term relationships with key industry stakeholders, the Senior Global Business Development Executive & Chief Revenue Officer drives sustainable revenue growth across multiple continents. This leadership role involves identifying strategic growth vectors and optimizing the sales pipeline to support the company's global mission. Through targeted business development, Liantonio strengthens the company's position as a premier partner for medical device innovation.
Adam Saltman - Chief Medical Officer, At Namsa
Adam Saltman, the Chief Medical Officer, At Namsa at NAMSA, provides clinical leadership and scientific oversight for all medical device research and development projects. Saltman ensures that clinical trials and regulatory submissions adhere to the highest medical standards and safety protocols. The Chief Medical Officer, At Namsa evaluates the clinical efficacy of new medical technologies and provides expert guidance to clients navigating complex regulatory pathways. Adam Saltman collaborates with laboratory and research teams to interpret clinical data and support evidence-based decision-making. By maintaining deep expertise in medical science, the Chief Medical Officer, At Namsa ensures that the company's consulting services remain at the forefront of clinical innovation. This role involves engaging with regulatory bodies and industry experts to advocate for patient safety and product quality. Through rigorous medical oversight, Saltman supports the company's commitment to accelerating the development of life-saving medical devices.

Explore Leadership Teams in Business Services
Brookings Institution operates as a nonprofit public policy research organization dedicated to generating actionable insights that address complex societal challenges. The organization conducts rigorous, in-depth research across multiple domains, translating academic inquiry into practical solutions for policymakers, business leaders, and civic stakeholders. Through its multidisciplinary approach, Brookings examines pressing issues spanning economics, governance, international affairs, and social policy, producing analysis that informs decision-making at local, national, and global scales. The institution's research methodology combines empirical investigation with expert analysis, drawing on scholars and practitioners who bring deep subject matter expertise to their work. Brookings produces comprehensive reports, policy briefs, and thought leadership that synthesize complex data into accessible recommendations. The organization's work spans both domestic policy challenges and international relations, reflecting the interconnected nature of modern governance and economic systems. Brookings maintains a commitment to nonpartisan analysis, striving to present evidence-based perspectives that transcend ideological boundaries. The institution engages with government officials, corporate executives, nonprofit leaders, and the broader public through publications, conferences, and direct consultation.
Company Leadership
SC

ST
The Urban Institute operates as a nonpartisan research organization committed to generating rigorous analysis and evidence-based insights on critical social and economic policy questions. Through empirical research and data-driven investigation, the organization works to inform public discourse and guide policymakers toward solutions that address complex societal challenges. The institute's work spans multiple dimensions of policy analysis, examining issues that directly affect communities and individuals across diverse socioeconomic circumstances. The organization maintains a multidisciplinary approach to research, bringing together economists, social scientists, and policy experts who collaborate to produce comprehensive studies and evaluations. This collaborative model enables the institute to examine interconnected policy challenges from multiple perspectives, generating nuanced findings that reflect the complexity of real-world problems. The research teams conduct original data collection, statistical analysis, and longitudinal studies designed to track outcomes and measure the effectiveness of various policy interventions. Urban Institute research addresses a broad spectrum of policy domains, including economic opportunity, education systems, health care access, housing markets, and government effectiveness.
Company Leadership JP

Barrios Technology is a woman-owned aerospace business that has been providing high-quality engineering, software, and technology integration solutions for over 45 years. They serve both government and commercial space flight programs, including significant contributions to NASA's human spaceflight initiatives. Their services encompass space mission integration, software engineering, systems engineering, and data analytics solutions. Barrios is committed to innovation and advancing humanity, both on and off the planet, while also supporting local communities through STEM-focused initiatives.
Company Leadership SL
KP
CG
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic.
Company Leadership

SY
